Variables | LPPPD n = 83 | LCP n = 20 | LSPDP n = 41 | P value | |
---|---|---|---|---|---|
P1 | P2 | ||||
Tumor size (cm) | 3.8 ± 1.1 | 2.8 ± 0.8 | 3.6 ± 2.2 | < 0.001 | 0.060 |
OT (min) | 300.4 ± 89.7 | 197.5 ± 30.5 | 174.8 ± 46.4 | < 0.001 | 0.027 |
Conversion (n, %) | 1 (1.2%) | 0 (0%) | 0 (0%) | 1.000 | NA†|
EBL (mL) | 140.0 (50.0–1000.0) | 50.0 (20.0–200.0) | 100.0 (20.0–300.0) | < 0.001 | 0.039 |
BT (n, %) | 2 (2.4%) | 0 (0%) | 0 (0%) | 1.000 | NA†|
POHS (days) | 11.0 (9.0–14.0) | 14.5 (12.3–23.0) | 10.0 (9.0–11.0) | < 0.001 | < 0.001 |
CR-POPF (n, %) | 3 (3.6%) | 8 (40.0%) | 3 (7.3%) | < 0.001 | 0.006 |
PPH (n, %) | 0 (0%) | 2 (10.0%) | 0 (0%) | 0.036 | 0.104 |
DGE (n, %) | 5 (6.0%) | 3 (15.0%) | 1 (2.4%) | 0.378 | 0.090 |
Reoperation* | 0 (0%) | 1 (5.0%) | 0 (0%) | 0.194 | 0.328 |
CL (n, %) | 1 (1.2%) | 0 (0%) | 0 (0%) | 1.000 | NA†|
Biliary fistula | 0 (0%) | 0 (0%) | 0 (0%) | NA†| NA†|
Complications (Clavien—Dindo ≥ Grade 3) | 2 (2.4%) | 4 (20.0%) | 0 (0%) | 0.012 | 0.009 |
90-Day mortality | 0 (0.0%) | 0 (0%) | 0 (0%) | NA†| NA†|
Follow-up | |||||
 Postoperative pancreatitis | 5 (6.0%) | 2 (10.0%) | 0 (0%) | 0.889 | 0.104 |
 Pancreatin treatment | 33 (39.8%) | 3 (15.0%) | 10 (24.4%) | 0.037 | 0.390 |
 Insulin treatment | 15 (18.1%) | 0 (0%) | 5 (12.2%) | 0.040 | 0.041 |